← All trials
NCT05568095
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 21, 2022
- Primary completion
- Sep 30, 2026
- Completion date
- Jan 31, 2027
- First posted
- Oct 5, 2022
- Last posted
- Dec 8, 2022
- Enrollment
- 970
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Arcus Biosciences, Inc.Lead sponsor
- Gilead SciencesCollaborator
- Arcus Biosciences, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.